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or Bone Marrow leads to Immune Recovery,
High Long-Term Donor Chimerism and Excellent
Survival in Chronic Granulomatous Disease
Priti Tewari,1 Paul L. Martin,1 Adam Mendizabal,2 Suhag H. Parikh,1 Kristin M. Page,1
Timothy A. Driscoll,1 Harry L. Malech,3 Joanne Kurtzberg,1 Vinod K. Prasad1The curative potential of hematopoietic stem cell transplantation in patients with chronic granulomatous dis-
ease depends on availability of a suitable donor, successful donor engraftment, and maintenance of long-term
donor chimerism. Twelve consecutive children (median age, 59.5 months; range, 8-140 months) with severe
chronic granulomatous disease (serious bacterial/fungal infections pretransplantation; median, 3; range, 2-9)
received myeloablative hematopoietic stem cell transplantation using sibling bone marrow ([SibBM]; n5 5),
unrelated cord blood (UCB; n 5 6), and sibling cord blood (n 5 1) at our center between 1997 and 2010.
SibBM and sibling cord blood were HLA matched at 6/6, whereas UCB were 5/6 (n5 5) or 6/6 (n5 1). Re-
cipients of SibBM were conditioned with busulfan and cyclophosphamide 6 anti-thymocyte globulin (ATG),
whereas 6 of 7 cord blood recipients received fludarabine/busulfan/cyclophosphamide/ATG. Seven patients
received granulocyte-colony stimulating factor-mobilized granulocyte transfusions from directed donors.
The first 2 UCB recipients had primary graft failure but successfully underwent retransplantation with
UCB. Highest acute graft-versus-host disease was grade III (n 5 1). Extensive chronic graft-vs-host disease
developed in 3 patients. All patients are alive with median follow-up of 70.5 months (range, 12-167 months)
with high donor chimerism (.98%, n5 10; 94%, n5 1; and 92%, n5 1). Myeloablative hematopoietic stem
cell transplantation led to correction of neutrophil dysfunction, durable donor chimerism, excellent survival,
good quality of life, and low incidence of graft-vs-host disease regardless of graft source.
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Chronic granulomatous disease (CGD), an
inherited disorder of phagocytic function secondary to
a loss or deficiency of phagocyte membrane proteins
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6/j.bbmt.2012.02.002about 1 in 200,000 individuals and often presents
with recurrent life-threatening bacterial and fungal
infections and/or granulomatous manifestations. Addi-
tionally, many patients develop aberrant immune-
mediated inflammatory responses that can result
in colitis, urinary tract obstruction, chorioretinitis,
gastric outlet obstruction, and chronic dysphagia [1].
Almost three-fourths of patients present before age 5
[2], with a wide spectrum of clinical phenotypes [3,4].
The use of prophylactic and aggressive antimicrobial
therapy and interferon-gamma has led to significant
improvements in survival and reduction in morbidity.
However, patients with severe phenotypes will have
major life-threatening infections during childhood
leading to significant mortality and morbidity partic-
ularly from fungal infections like aspergillosis, which
may account for one-third of all deaths. Furthermore,
patients with CGD with severe functional phenotype
(lowest oxidant production) who survive childhood
face high mortality after 20 years of age, likely a result
Biol Blood Marrow Transplant 18:1368-1377, 2012 1369UCBTand BMT for CGDof cumulative organ injury from recurrent infection and
CGD-related inflammatory disease [5].
Hematopoietic stem cell transplantation (HSCT)
is currently the only curative therapy for patients
with CGD whereby engrafted donor cells correct the
neutrophil killing defect and immune deficiency by re-
placing abnormal nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase-producing phagocytic
cells. The long-term benefit of HSCT depends on sus-
tained high levels of donor chimerism and continuous
production of donor-derived cells for the rest of the re-
cipient’s life. Barriers to successful outcomes of HSCT
in CGD include increased resistance to engraftment,
existing comorbidities related to prior infections and
granulomas, and increased risk of transplantation-
related mortality. Additionally, access to transplanta-
tion and the availability of a suitable donor are equally
important factors. Most of the published data on
HSCT for CGD pertains to the use of bone marrow
grafts from HLA-matched siblings [6,7]. However,
matched sibling donors are only available for about
25% of patients. For the remainder, alternative graft
sources must be found. A recent article describes
good outcome in 7 patients undergoing unrelated
bone marrow transplantation (BMT) after
myeloablative conditioning [7]. However, availability
of unrelated bone marrow donors is limited for many
racial and ethnic minority patients. Unrelated umbili-
cal cord blood donors offer the advantages of faster
availability, higher probability of finding a suitable
match, lower incidence of graft-versus-host disease
(GVHD), and no risk to the donor [8-10]. This
report underscores the success of myeloablative
HSCT using cord blood and bone marrow grafts
from related and unrelated donors to treat pediatric
patients with severe CGD and highlights the
importance of early transplantation, good infection
control, and aggressive supportive care.MATERIALS AND METHODS
Patients
Twelve consecutive pediatric patients with CGD,
with histories of multiple infections and thus consid-
ered to have clinically severe disease, underwent
HSCT after myeloablative conditioning at Duke
University Medical Center between August 1997 and
June 2010. All patients with CGD who underwent
HSCT during this period were included in the
study. All patients were enrolled in a Duke University
Medical Center Institutional Review Board approved
protocol or treatment plan for transplantation.
Written informed consent was obtained for all patients
according to the Declaration of Helsinki. Preliminary
data on patients no. 5 and no. 7 were previously pub-
lished [11].Graft Sources
Sibling donors were genotypic matches at 6/6 or
10/10 HLA loci. Bone marrow was harvested from
the iliac crest using standard methods on the day of
transplantation. Bone marrow from ABO-mismatched
donors were depleted of red blood cells and/or plasma
as needed before infusion to the recipient. Marrows
were not manipulated in any other way. Cord blood
donors were typed at low resolution for HLA class I
(A and B loci) and high resolution for HLA-DRB1.
A minimum match of 4/6 (using low to intermediate
resolution matching at HLA class I and high-resolu-
tion matching at HLA class II) was required for unre-
lated cord blood donor/recipient pairs. Cord blood
donors were procured through the National Marrow
Donor Program ‘‘Be the Match’’ registry. On the day
of transplantation, cord blood units were thawed and
washed [12] before infusion.Conditioning Regimens
All patients were cytoreduced using fully myeloa-
blative regimens. As summarized in Table 1, pretrans-
plantation conditioning regimens were as follows:
sibling bone marrow (SibBM) patients (n5 5) received
intravenous (IV) busulfan (1 mg/kg/dose or 40 m2/
dose every 6 hours 16 doses over 4 days), cyclophos-
phamide (50 mg/kg/dose) daily for 4 days 1/2 anti-
thymocyte globulin (ATG), sibling cord blood
(SibCB) (n5 1), and 5 of 6 patients with UCB received
fludarabine (25 mg/m2/dose, daily for 3 doses), IV bu-
sulfan (1 mg/kg/dose or 40 mg/m2/dose every 6 hours
for 4 days), cyclophosphamide (50 mg/kg/day for
4 days), and equine ATG (30 mg/kg/dose, daily 
3 days). Busulfan pharmacokinetics was studied after
the first dose, and subsequent doses were adjusted to
maintain a steady state of 600 to 900 ng/mL. Three
patients underwent 2 transplantations each. One
(patient no. 3) had graft failure after a matched, related
donor, T cell-depleted graft after reduced-intensity
conditioning (RIC) with fludarabine and cyclophos-
phamide at another institution. He received fludara-
bine, busulfan, cyclophosphamide, and ATG for his
subsequent transplantation. The other 2 patients had
received myeloablative conditioning and cord blood
graft at our institution. Patient no. 5 had initially re-
ceived busulfan, cyclophosphamide, and ATG as prep-
aration for his first transplantation. For the second
transplantation, he received a single dose of total
body irradiation (200 cGy), cyclophosphamide
(50 mg/kg/dose) for 1 dose and fludarabine (40 mg/
m2/dose, daily for 5 days). Patient no. 7 had received
fludarabine, busulfan, cyclophosphamide, and equine
ATG as conditioning for his first transplantation.
His second transplantation conditioning regimen con-
sisted of campath (anti-CD52 antibody; 0.9mg/kg/day
for 5 days), fludarabine (25 mg/m2/dose, daily for
Table 1. Graft and Transplant Characteristics
Patient
Number
Donor
Source
HLA Match
(of 6)
Total Nucleated
Cell Dose ( 107/kg) GVHD Prophylaxis
Granulocyte
Infusions Conditioning Regimen
1 SibBM 6 79.4 CSA/MTX No Busulfan/cytoxan
2 SibBM 6 16.6 CSA/MTX No Busulfan/cytoxan
3aa SibBM 6 NA CSA/TCD No Fludarabine/cytoxan + eATG
3b SibBM 6 40 CSA/MTX No Fludarabine/busulfan/cytoxan + rATG
4 SibBM 6 34.8 CSA/MTX No Busulfan/cytoxan
5aa UCB 5 4.15 CSA/steroid Yes Busulfan/cytoxan + eATG
5b UCB 5 4.14 CSA/steroid Yes TBI (200 cGy)/fludarabine/cytoxan
6 SibBM 6 55 CSA/MTX No Busulfan/cytoxan + eATG
7aa UCB 5 8.5 CSA/MMF Yes Fludarabine/busulfan/cytoxan + eATG
7b UCB 4 6.87 CSA/MMF Yes Campath/fludarabine/cytoxan
8 UCB 5 3.47 CSA/MMF Yes Fludarabine/busulfan/cytoxan + eATG
9 UCB 5 4.8 CSA/MMF Yes Fludarabine/busulfan/cytoxan + eATG
10 SibCB 6 3.2 CSA/steroid Yes Fludarabine/busulfan/cytoxan + eATG
11 UCB 5 12.6 CSA/MMF Yes Fludarabine/busulfan/cytoxan + eATG
12 UCB 6 11.2 CSA/MMF Yes Fludarabine/busulfan/cytoxan + eATG
GVHD indicates graft-versus-host disease; SibBM, sibling bone marrow; CSA, cyclosporine A; MTX, methotrexate; NA, not available; TCD, T cell
depleted; eATG, equine ATG; rATG, rabbit ATG; UCB, unrelated cord blood; TBI, total body irradiation; MMF, mycophenolate mofetil; SibCB, sibling
cord blood.
aPatients who underwent 2 transplantations.
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for 2 days).
GVHD Prophylaxis
GVHD prophylaxis (Table 1) consisted of stan-
dard cyclosporine A (CSA) with methotrexate on
days 1, 3, 6, and 11 for all SibBM transplantations
[13]; cord blood transplantation recipients received
CSA with either 45 mg/kg/day mycophenolate mofetil
(n5 5) or 1 mg/kg/day of methylprednisolone (n5 2).
Methylprednisolone was preferred in patients who had
been on prior steroids due to a history of colitis or
other immune or inflammatory problems. In cord
blood recipients, CSA was administered for 9 months
and then tapered over 2 to 3 months, if there was no
active GVHD. In SibBM, cyclosporine was tapered
after 6 months. Methylprednisolone or mycopheno-
late mofetil was continued for 2 to 3months in patients
without ongoing GVHD. Acute GVHD (aGVHD)
and chronic GVHD (cGVHD) were scored according
to standard criteria [14,15].
Supportive Care Measures
Patients were admitted to reverse isolation rooms
on a dedicated pediatric transplantation unit with
positive pressure ventilation and high-efficiency par-
ticulate air filtration. Standard prophylaxis against
viral pathogens and Pneumocystis carinii was used.
Fungal prophylaxis was administered with low-dose
amphotericin-B until 1999 and with voriconazole
thereafter. Empiric broad-spectrum antibiotic therapy
was started with the first fever. IV immunoglobulin
(500 mg/kg per dose) was given weekly until day 100
and then ‘‘as needed’’ to maintain immunoglobulin
levels greater than 500 mg/dL until discontinuation
of GVHD therapy and documentation of antibody
production. Veno-occlusive disease prophylaxis wascontinuous infusion heparin (100 units/kg/day) from
day -10 to day 128. Patients received total parenteral
nutrition and transfusions of leukocyte-depleted and
irradiated packed red cells and platelets as needed.
Granulocyte colony-stimulating factor (G-CSF)
(10 mcg/kg/day) was given IV daily starting on day
0 and continued until a white blood cell (WBC) count
of 5  109/L or higher was achieved.
Granulocyte Transfusions
G-CSF-mobilized, irradiated granulocyte transfu-
sions were used during neutropenia to prevent serious
infections in patients undergoing cord blood trans-
plantations. Granulocyte donors were either parents
or other family members who underwent medical
and blood product donor clearance followed by the
placement of a central venous line. G-CSF (10 mcg/
kg) was given subcutaneously the night before phere-
sis, which was performed twice weekly, 3 to 4 days
apart. Donors were supported with oral iron, vitamin
K, and calcium supplements. Each pheresis product
was irradiated to prevent engraftment and subse-
quently divided into 3 aliquots with a maximum dose
of 5  109 cells/kg of recipient body weight. Granulo-
cytes were plasma and/or RBC depleted if the blood
types of the recipient, granulocyte donor, and stem
cell donor were not compatible. Twice-weekly phere-
sis allowed daily granulocyte transfusions 6 days per
week. Patients received granulocyte infusions until
sustained engraftment with a WBC count over 5,000
and no active infections. Engraftment was evaluated
based on rising WBC counts beginning the day after
the patient did not receive granulocytes.
Follow-up
Patients underwent neutrophil functional assays,
blood chimerism testing, immune function studies,
Table 2. Patient Characteristics
Patient
Number
Age at HCT
(months) Gender Mutation Inheritance Pretransplantation Infectionsa
1 8 F Unknown AR Colitis, bronchiolitis, thrush
2 25 M Unknown AR Diffuse Candida peritonitis, thrush
3 56 M gp91phox X-linked Multiple pneumonias, apthous ulcers
4 17 M Unknown AR Burkholderia pneumonia
5 122 M gp91phox X-linked Pneumonias, lung aspergilloma, multiple osteomyelitis, salmonella gastroenteritis
6 109 M p22phox AR Serratia osteomyelitis, mycobacterium skin nodules, resistant lung acid-fast
bacilli, bladder granulomas
7 18 M gp91phox X-linked Staphylococcal skin infection, lymphadenitis, pulmonary nodules
8 100 M gp91phox X-linked Kidney granulomas, pneumonia, colitis
9 140 M gp91phox X-linked Nocardia pneumonia, gut mucormycosis, sinusitis, colitis
10 73 M gp91phox X-linked Klebsiella abscess, pulmonary nodules, multiple pneumonias, gingivitis, colitis
11 14 M gp91phox X-linked MRSA liver abscess, Staphylococcus aureus neck abscess, mediastinal cyst
12 46 M gp91phox X-linked Serratia abscess, apthous ulcers
HCT indicates hematopoietic cell transplantation; AR, Autosomal Recessive; X-linked, X Chromosome linked; MRSA, methicillin-resistant Staphylococ-
cus aureus.
aPatients had a median of 3 serious infections (range, 1-6) by the time they underwent stem cell transplantation.
Biol Blood Marrow Transplant 18:1368-1377, 2012 1371UCBTand BMT for CGDand other routine posttransplantation multisystem
evaluations at day 100, 6months, 9months, 12months,
and then yearly posttransplantation or whenever clini-
cally indicated.
Statistics
Descriptive analyses were conducted using patient
data obtained through July 2011. Patient listings are
provided as are time-to-event analyses. The Kaplan-
Meier estimator was used to describe overall survival
(OS) and event-free survival (EFS) [16]. OS considered
a patient death as the event and censored on the last
date of contact, whereas EFS considered either graft
failure or death as the event. The cumulative incidence
estimator [17] was used to describe the probability of
an event occurrence such as neutrophil engraftment,
platelet engraftment, or GVHD. Engraftment was
defined as the first day of an absolute neutrophil count
of .0.5  109/L for 3 consecutive days not secondary
to granulocyte infusions, and platelet engraftment
was defined as platelet counts .20  109/L or
.50  109/L for 7 consecutive days without platelet
transfusions. For patients receiving granulocytes (days
1-6 of the week), engraftment was determined on the
basis of absolute neutrophil count on the day after the
‘‘off’’ day for granulocyte transfusion. Intra- and post-
transplantation complications, respiratory burst assays,
and performance statuswere evaluated using descriptive
measures.RESULTS
Patient Demographics
All patients were diagnosed by respiratory burst
assays. Mutation analysis data was available for 9 of
12 patients. Patient characteristics are presented in
Table 2. Eight patients had the X-linked Gp91phoxmutation of the CYBB gene; the remaining 4 had auto-
somal recessive inheritance. Eleven patients were
men, and 8 were white. Three patients were cytomeg-
alovirus (CMV) seropositive pretransplantation.
There were 2 sets of affected siblings within the co-
hort. The patients underwent transplantation at a me-
dian age of 59.5 months (range, 8-140 months) and
weighed a median of 16.9 kg (range, 9-60 kg). Their
weight-for-age percentile ranged from \5th to the
75th. However, 5 patients were below the 5th percen-
tile at the time of transplantation. At the time of trans-
plantation, all patients had a performance status score
of 80 to 100 (Lansky) with cardiac, lung, and renal
function in the normal range. One patient had a history
of urethral polyps, and 4 of 12 patients had a history of
extensive colitis requiring treatment with systemic cor-
ticosteroids before transplantation.Pretransplantation Infections
All patients had suffered multiple episodes of seri-
ous bacterial and/or fungal infections before trans-
plantation (Table 2). These infections included
Candida peritonitis, Klebsiella abscess, hepatic abscess,
gut mucormycosis, peritonitis, osteomyelitis, and mul-
tiple pneumonias. One patient presented with a large
invasive lung and chest wall aspergilloma. This patient
required treatment with interferon-gamma, voricona-
zole and caspofungin, and granulocyte transfusions
for almost a year to successfully control his aspergil-
loma before proceeding toHSCT.One pair of siblings
(patients no. 8 and no. 9) had histories of fungal pneu-
monias partially treated with fluconazole, itracona-
zole, and posaconazole at the time they presented for
transplantation. Patient no. 10 presented with a long
history of pulmonary nodules, which had been previ-
ously biopsied. At presentation to our institution, he
had multiple areas of scarring and ground-glass ap-
pearance before transplantation. Infections were
Table 3. Transplantation Outcomes
Patient
Number
Neutrophil
Engraftment Day
Platelet
Engraftment Day
Follow-up
Duration (years)
aGVHD
Grade
aGVHD
Location cGVHD Transplant Complications
Donor
Chimerism
1 18 40 13.9 0 None None 98%
2 20 59 13.5 0 None Coagulase negative
Staphylococcal
bacteremia
98%
3 16 33 8 2 Gut Limited skin None 94%a
4 11 39 7 0 None Streptococcus viridans
bacteremia,
parainfluenza 3
98%
5 32 74 6.33 3 Skin Extensive gut & skin Autoengrafted initial
transplantation, urine
polyoma virus, ITP
>98%a
6 16 40 6.5 1 Skin None Pancreatitis >98%
7 16 - 5.4 1 Skin None Autoengrafted initial
transplantation
>98%a
8 29 170 3.6 2 Skin Extensive gut & skin Gram-positive cocci
bacteremia, stool C.
difficile infection, bladder
granuloma, pericardial
effusion
>98%
9 43 36 3.6 2 Skin Extensive skin CMV viremia, urine
polyoma virus, ITP
>98%
10 29 72 2 1 Skin None CMV viremia, urine
polyoma virus infection,
idiopathic pneumonia
syndrome
92%
11 18 70 1.4 2 Skin None ITP >98%
12 19 43 1 2 Skin None Parainfluenza 3 98%
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; ITP, Immune Thrombocytopenic Purpura; CMV, cytomeg-
alovirus.
aChimerism after second transplantation, patient no. 7 did not have platelet aplasia during his second transplantation.
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tient had a clinically active infection at the time of
starting cytoreduction. All patients had failed prophy-
laxis with antibiotics and 8 of 12 had also failed prior
treatment with interferon.Graft Characteristics
Graft sources (Table 1) were matched SibBM in 5,
unrelated donor cord blood (UCB) in 6, and SibCB in
1 patient. SibBM and SibCB donors were genotypic
HLA matches at 6/6 or 10/10. UCB units for the
first transplantation matched at 5/6 (n 5 5) or 6/6
(n 5 1) loci using low-resolution typing for HLA-A
and HLA-B and high-resolution typing for HLA-
DRB1. The HLA matching of UCB units used for
second transplantation were 4/6 (n 5 1) and 5/6
(n 5 1). The cord blood units contained a median
pre-cryopreservation total nucleated cell dose of
4.87  107 cells/kg (range, 3.2-12.6  107 cells/kg)
and a median CD34 dose of 2.0  105 cells/kg (range,
1.1-5.0  105 cells/kg). SibBM contained a median to-
tal nucleated cell dose of 4.03  108 cells/kg (range,
1.66-7.94  108 cells/kg) and a median CD34 dose of
6.02  106/kg (range, 3.86-22.71  106 cells/kg).
ABO mismatched bone marrows underwent red
cell and/or plasma depletion and were washed before
transplantation.Survival and Quality of Life
At the time of the analysis, all patients were alive
and disease free with a median follow-up of 70.5
months (range, 12-167 months) as shown in Table 3.
No new infection episodes were seen in any patient af-
ter 8 months posttransplantation. All but 1 patient
with cGvHD (Lansky 60) have Lansky scores of 80
to 100. All school-age children returned back to full-
time school within 18 months after transplantation.Engraftment
All patients engrafting after their first transplanta-
tion achieved neutrophil engraftment by day 43 post-
first transplantation with a cumulative incidence of
83.3% (95% confidence interval [CI], 55.2-100.0;
Figure 1). Two patients failed to engraft with their
first transplantation but engrafted after a second trans-
plantation that was performed on days 62 and 63 post-
first transplantation, respectively. In the patients
engrafting after the first transplantation, neutrophil
engraftment occurred in a median of 16 days (range,
11-20 days) in bone marrow and 29 days (range,
16-43 days) in cord blood recipients. Overall, the me-
dian time to neutrophil engraftment was 20 days with
a range of 11 to 43 days. When considering graft fail-
ure as an event, the 6-month EFS probability was
83.3% (95% CI, 48.2% to 95.6%).
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Figure 1. Cumulative incidence of neutrophil engraftment to
0.5  109/L after the first transplantation.
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tion achieved platelet engraftment .20,000  109/L
(20K) and .50,000  109/L (50K) within 180 days.
Platelet engraftment .20K occurred in a median of
34 days (range, 26-160 days) in the whole group;
31.5 days (range, 29-54 days) in the bone marrow
group, and 42.5 days (range, 26-160 days) in the cord
blood group, respectively. Platelet engraftment
.50K occurred in a median of 43 days (range, 33-
170 days) in the whole group; 40 days (range, 33-59
days) in the bone marrow group, and 71 days (range,
36-170 days) in the cord blood group, respectively.
Two UCB transplantation recipients had graft failure
as described earlier, but both engrafted successfully
after the second UCB transplantation [11].Pr
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Figure 2. (A) Cumulative incidence of grades II to IV and III to IV acute graft-v
GVHD (cGVHD) and of extensive chronic GVHD.Granulocyte Transfusions
Seven patients underwent granulocyte transfusion
in the posttransplantation period. Themedian number
of transfusions per patient was 24 (range, 12-36) with
a median duration of 4 weeks (range, 2-6 weeks).GVHD
AGVHD (Figure 2A) developed in 9 patients and
was limited to the skin in 8 (grade 1 in 3 patients and
grade 2 in 5 patients). The overall cumulative inci-
dence estimate by day 100 of grade II to IV aGVHD
was 33.3% (95% CI, 7.3-59.3). Grade III aGVHD of
the gut developed in 1 patient who had undergone
a second transplantation. Five patients developed
cGVHD, 2 limited to the skin and 3 with extensive dis-
ease. One of these patients initially developed exten-
sive skin and gut cGVHD, which progressed to
a macrophage-activation-like syndrome with multifo-
cal arthritis, fevers, and cytopenia. He responded to
interleukin-1 receptor antagonist therapy. The cumu-
lative incidence estimate of overall cGVHD at 2 years
was 33.3% (95% CI, 7.3-59.3) and of extensive
cGVHD was 26.7% (95% CI, 1.8-516; Figure 2B).
Three patients developed immune thrombocytopenia
in the posttransplantation period. They were success-
fully treated, 2 with steroids and rituximab and 1
with steroids alone.
Infections and Other Posttransplantation
Complications
Two patients (no. 9 and no. 10) had CMV reactiva-
tion requiring treatment, 3 patients (no. 2, no. 4, and no.
8) had uncomplicated gram-positive bacteremia, 3 pa-
tients (no. 5, no. 9, and no. 10) had urine polyoma virus
infections, 1 patient (no. 6) had mild pancreatitis,Pr
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cardiocentesis, and 1 patient (no. 10) required treatment
for idiopathic pneumonia syndrome.Patient no. 10with
idiopathic pneumonia syndrome, is currently 18months
posttransplantation, physically active with no oxygen
requirement, and has normal lung function tests. Peri-
cardial fluid in patient no. 8 was exudative in nature
and negative by PCR for HHV-6, EBV, CMV,
adenovirus, parvovirus B-19, and AFB smear, bacterial,
viral, and fungal cultures. One patient developed
macrophage-activation-like syndrome, as described in
the previous section. No patient developed any new in-
fections after 8 months posttransplantation.
Chimerism
By day 100, all patients had .90% donor chime-
rism, and at their most recent follow-up, donor chime-
rism in whole blood was .98% in 10 patients, 94% in
1 patient (no. 3), and 92% in another patient (no. 10).
At the last follow-up, all patients had normal respira-
tory burst assays and/or dihydrorhodamine fluores-
cence cytometry and were free of infection.DISCUSSION
Results from our cohort of patients with severe
CGD undergoing HSCT showed that myeloablative
HSCT is successful and results in long-term survival,
low incidence of GVHD, freedom from infections,
and improved quality of life if performed early in the
course of the disease and with aggressive supportive
care. Most of the published data describe the use of re-
lated or unrelated bone marrow in patients who under-
went transplantation at multiple centers. Our study
involves a consecutive series of patients including 7
with cord blood grafts who underwent transplantation
at a single center utilizing uniform supportive care and
cytoreduction.
Soncini et al. [18] reported the outcome in 20 pa-
tients who underwent transplantation between 1998
and 2007 using matched SibBM (n 5 9), matched
SibCB (n 5 1), unrelated matched bone marrow
(n 5 6), unrelated matched peripheral blood stem
cell (PBSC; n 5 2), mismatched PBSC (n 5 1), and
mismatched UCB (n 5 1). Four patients underwent
the RIC regimen. Overall survival was 90%, and 2 pa-
tients required a subsequent bone marrow boost to
maintain adequate neutrophil oxidative burst. The 2
patients that did not survive underwent RIC condi-
tioning and died from disseminated fungal infections
[18]. Schuetz et al. [19] reported the outcomes of 12
patients with CGD, 6 of whom underwent transplan-
tation with matched unrelated bone marrow, 3 with
matched PBSC, and 3 withmatched SibBM, 9 received
myeloablative conditioning, and 3 received RIC. OS
was 75%, with 67% survival in the group undergoingmyeloablative conditioning. In addition, 1 of the 3 pa-
tients undergoing transplantation with RIC had autol-
ogous recovery [19]. In a retrospective registry-based
study of 27 patients, Seger et al. [20] reported the Eu-
ropean experience from 1985 to 2000 from 14 centers.
Twenty-three patients had received myeloablative,
and 4 had received RIC. The OS at a median follow-
up of 24 months was 92% and 75% in the myeloabla-
tive and reduced-intensity cohorts, respectively. It is
crucial to note that only half of the patients receiving
RIC had successfully engrafted. Martinez et al. [7] re-
ported excellent outcomes of 11 children who under-
went transplantation at a single center. With 7
receiving unrelated matched bone marrow and 4 re-
ceiving matched SibBM, all patients are alive at a me-
dian of 2.5 years, and 9 of the 11 patients achieved
full-donor chimerism [7]. G€ung€or et al. [21] reported
the outcomes of 11 patients receiving RIC using
busulfan at a total dose of 8 mg/kg, fludarabine at a to-
tal dose of 180 mg/m2 and 4 days of ATG, undergoing
bone marrow (n 5 10) or PBSC (n 5 1) transplanta-
tions. There was 1 death in that cohort [21]. Outcomes
of our cohort as measured by OS and sustained donor
chimerism compare favorably with the published re-
ports of HSCT using matched sibling, unrelated
bone marrow, as well as unrelated PBSC in patients
with CGD.
Patients with CGD are prone to graft failure after
HSCT, whichmay largely be explained by exaggerated
immune responses [22]. The first reported transplanta-
tion for CGDdeveloped graft rejection 2months post-
transplantation [23]. Prior infections and resultant
organ dysfunctions may also increase transplantation-
related complications, particularly if patients undergo
transplantation later in the course of their disease. In
recent years, there has been significant interest in
RIC as an option to decrease chemotherapy-related
toxicity and limit transplantation-related mortality
and morbidity. However, there has been limited suc-
cess with this modality. In a study published in 2001,
10 patients with CGD were treated with T cell-
depleted,matched-siblingPBSCtransplantations.With
amedian follow-upof 17months (range, 8–26months),
1 patient had graft failure, 1 had graft rejection, and
there were 3 fatalities. Whereas 7 of 10 patients in
this cohort were alive at the time of publication, the
rate of high (.90%) donor chimerism in the myeloid,
as well as lymphoid fractions was low [24]. Various in-
vestigators have considered the use of RIC to decrease
the short- and long-term toxicity of transplantation. In
the European cohort, 3 of 4 patients who underwent
RIC transplantations developed graft failure [20] with
1 patient recovering donor chimerism after donor leu-
kocyte infusion. With the success of HSCT in CGD
critically dependent on achieving a high level of donor
chimerism and maintaining it over the long term,
limited experience from RIC-HSCT suggests that
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Biol Blood Marrow Transplant 18:1368-1377, 2012 1375UCBTand BMT for CGDlower immunosuppression in this context is associated
with a higher incidence of graft failure.
All patients with severe CGD are at high-risk
regimen-related toxicity because of previous infec-
tions, altered and hyperactive immune system, and or-
gan dysfunctions. Despite the young age of our patient
cohort, all had developed multiple serious infections
before being referred for transplantation. These infec-
tions required hospitalizations, surgery, and prolonged
antimicrobial therapy. We elected to support some of
these patients with supplemental transfusions of irradi-
ated, directed donorG-CSFmobilized granulocytes to
help reduce or control infections during their aplasia in
the first month posttransplantation. This approach
may have contributed to improved outcomes, particu-
larly in recipients of cord blood grafts.
The negative impact of pretransplantation infec-
tions on transplantation outcomes was highlighted
by Segar et al. [20] in a registry-based EuropeanGroup
for Blood and Marrow Transplantation retrospective
study of 27 BMT performed between 1985 and 2000
at 14 centers [20]. Sixteen patients were considered
high risk due to either disseminated infection or
significant pulmonary restrictions. Four of the 16
underwent RIC. The disease-free survival rate in the
high-risk group was 69%, and the OS was 75%. No
patient died in the low-risk group, whereas in the
high-risk group, 4 patients died, and 3 had autologous
recovery [20]. It may be possible to lower regimen-
related toxicity by performing transplantations early
in the course of the disease before repeated infections
and cumulative effects of an overactive immune system
have taken a toll on various organ systems and pushed
the patients in the ‘‘high-risk’’ category. The outcomes
could also be improved by providing excellent sup-
portive care including optimization of pretransplanta-
tion infection control, aggressive management of intra
transplantation infections, and the use of granulocyte
transfusion during the neutropenic period for select
patients. For example, patient no. 5, a 10-year-old
boy who presented with a visible deformity of his chest
wall secondary to a large active aspergilloma, was biop-
sied and then aggressively treated with caspofungin,
voriconazole, and interferon-gamma, followed by
granulocyte infusions during the transplantation pe-
riod. He successfully underwent transplantation and
is currently over 6 years posttransplantation and dis-
ease free. Additionally, the impact of pulmonary issues
on the outcomes is particularly important. Lungs are
frequently diseased in patients with CGD due to re-
peated bacterial and fungal infections, noninfectious
granulomas, and sometimes from the impact of surger-
ies. Most of these complications increase with age, and
it is likely that a younger patient with CGD will, in
general, have healthier lungs. High rate of survival
and low incidences of complications in our patients
reflects transplantation at a younger age, high
Table 5. Summary of Current Series and Published Data on CBT for CGD
Source Center or Group
Donor Source
(no. of patients) Conditioning
Median
Follow-up
(months)
OS
(%)
Engraftment
(%)
Patients Achieving
High (>90%)
Donor Chimerism
Tewari, 2012 Duke University Medical Center U-M-CB (5), U-MM-CB (1),
R-M-CB (1)
MAC 44 100 100 100
Jaing, 2010 Chang Gung Children’s Hospital U-MM-CB (1) MAC 8 100 100 100
Goussetis, 2010 Aghia Sofia Children’s Hospital R-M-CB (2) MAC 15.5 100 100 100
Soncini, 2009 UK Northern Supra Regional
HSCT Unit
R-M-CB (1), U-MM-CB (1) MAC 61 100 100 50
Mochizuki, 2009 Fukushima Medical University
School of Medicine
U-MM-CB (1) RIC 36 100 100 100
Suzuki, 2007 Sapporo Medical University
School of Medicine
U-M-CB (1) RIC 14 100 100 100
CBT indicates cord blood transplantation; CGD, chronic granulomatous disease; OS, overall survival; U-M-CB, unrelated matched cord blood; U-MM-
CB, unrelated mismatched cord blood; R-M-CB, related matched cord blood; MAC, myeloablative conditioning; HSCT, hematopoietic stem cell trans-
plantation; RIC, reduced-intensity conditioning.
1376 Biol Blood Marrow Transplant 18:1368-1377, 2012P. Tewari et al.pretransplantation Lansky scores, near-normal organ
function in most patients, and implementation of ag-
gressive supportive care measures. While it is under-
standable that physicians and parents may be
reluctant to refer children who seemwell for a complex
therapy like HSCT, our data suggest that early trans-
plantation when organs are still in a good functional
state is optimal and can lead to excellent outcomes.
Most of the published data on HSCT in CGD
involves the use of matched-SibBM (Table 4)
[18-20,24-26]. However, the probability of finding
a matched sibling donor in most populations is about
25%, and in fact, even lower within siblings of
patients with genetic diseases. For the remainder of
patients, an alternate donor source including
unrelated bone marrow, haploidentical related
donor, or UCB units should be found. The reported
survival and long-term donor chimerism after unre-
lated BMTand PBSC is relatively lower [27], and there
are no published data on haploidentical transplanta-
tion in CGD. Published data on the use of cord blood
as a graft source in CGD is limited to a total of 7 pa-
tients in 5 case reports describing 3 unrelated and 4 re-
lated cord blood transplantions (CBT) [18,28-32]
(Table 5). It is certainly possible that other cases of
CBT with poor outcomes have not been reported in
the literature. Various cytoreductive regimens and
GVHD prophylaxis were used in the published re-
ports. In contrast, our cohort consists of 6 unrelated
and 1 related CBT patient who underwent transplan-
tation using a uniform regimen and, to our knowledge,
is the largest cohort of CBTs for CGD. It is important
to note that all CBT recipients are alive and well with
high donor chimerism. Despite small numbers, our
study highlights the potential of using this valuable
graft source to achieve long-term success. We believe
that the use of unrelated UCB is a feasible option for
patients lacking matched sibling donors.
CGD has a wide clinical spectrum ranging from
patients with trivial, infrequent infections to those
with repeated life-threatening infections early in life.This clinical variability must be taken into consider-
ation when making therapeutic decisions regarding
the use of prophylactic antibiotics, various supportive
care measures, interferon, and HSCT. Despite exten-
sive laboratory research, gene therapy is currently
not available for clinical use leaving HSCT as the
only curative option. Criteria for identifying appropri-
ate transplantation candidates, in particular those that
are early in the disease course, are yet to be developed.
Our data suggest that patients with severe phenotype
CGD who develop early immunologic or inflamma-
tory problems or multiple serious infections should
undergo transplantation early. In this report, we pres-
ent evidence that HSCT using a variety of donor and
graft sources including UCB units after myeloablative
conditioning results in durable engraftment and
excellent long-term survival, regardless of graft source.
Correction of aberrant phagocytic function and
immune-mediated inflammation, prevention of
new infections, with an acceptable incidence of
transplantation-related morbidity was seen. We con-
clude that HSCT, including those using UCB donors,
should be considered early in pediatric patients
with severe phenotype CGD early in the course of
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